trial of adherence app for buprenorphine treatment (taab) study

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to pilot test a smartphone application that allows video-based directly observed therapy for participants receiving buprenorphine treatment for opioid use disorder in office-based settings. this application may help participants take their medication more regularly so that they are successful in treatment. participants will be randomly assigned to either using a smartphone application that allows them to take daily videos confirming their buprenorphine medication ingestion or they will continue with their care as usual (treatment-as-usual or tau). the primary study outcome will be the percentage of weekly study urine drug tests that are negative for opiates between baseline and 12 weeks post-randomization. the secondary outcome will be engagement in treatment at week 12.

the objective of this study is to compare an innovative mobile health (mhealth) platform to support participants being treated for opioid use disorder (oud) with buprenorphine to treatment-as-usual (tau). the application will provide video-based directly observed therapy (vdot) which may result in better health outcomes for participants and less public health risk for diversion. this study is a randomized controlled trial with two arms: tau and mhealth intervention. randomization to the two study arms will be completed using computer randomization procedures. participants in the intervention group will learn how to use the mhealth application on their personal smartphones or tablets. if a participant does not have access to a personal device or prefers to not use a personal device then a study-provided smartphone will be offered for the duration of the study. intervention participants are asked to record one daily video of themselves taking buprenorphine. buprenorphine clinical staff (i.e., physicians, nurses and medical assistants) of patients enrolled in the intervention group will be trained and have the opportunity to review the videos. adherence for the intervention group will be measured through participation in vdot, namely the percentage of daily medication doses that are observed through submitted videos. the tau group will not be given access to the intervention and therefore will not have the opportunity to be exposed to the intervention. all participants will follow the same visit schedule. interviews will occur at baseline (week 0) and the final visit (week 12) to assess current and prior substance use, treatment history, medication adherence, drug diversion, general physical and mental health and treatment satisfaction. a point of care urine drug test will also be administered which will assess for opiates and other substances. in between the baseline and final visits, participants will meet with research staff weekly to conduct a urine drug test and assess self-reported adherence to buprenorphine. research staff will review the electronic medical record at baseline and week 12 to assess engagement in treatment. additionally, at 24 weeks post-enrollment the research staff will complete a review of the electronic medical record and record engagement in clinic treatment, changes in buprenorphine treatment during the study period and the results of any clinical urine drug testing.

Eligibility criteria:
inclusion criteria: * ≥18 years old * receiving buprenorphine treatment at an office-based buprenorphine program for ≤4 weeks * willing to be randomized to either vdot or tau exclusion criteria: * unable or unwilling to use smart phone * cognitive impairment resulting in inability to provide informed consent * researcher's discretion that participant will not be appropriate for participation in the study (e.g. participant is planning on moving away, is knowledgeable of future incarceration during the study, or has behavioral issues that may pose safety concerns for clinic and research staff) * inability to read and understand english as needed for following app instructions

Keywords: buprenorphine directly observed therapy mhealth opioid abuse